Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-03-08
2005-03-08
Barts, Samuel (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S051000, C536S025600
Reexamination Certificate
active
06864243
ABSTRACT:
The present invention provides a method of preventing or treating retinal degeneration arising from pathophysiological or physical conditions. The method comprises administering to a patient a pharmaceutical composition comprising a purinergic P2Y receptor ligand, in an amount effective to elevate its extracellular concentration to activate retinal glial and neuronal cell surface P2Y receptors and mount a neuroprotective response. Methods of administering including intravitreal bolus and sustained administrations, transscleral delivery, topical, and systemic administrations. The pharmaceutical composition useful in this invention comprises a P2Y purinergic receptor agonist, which include uridine 5′-di-and triphosphate (UDP, UTP) and their analogs, adenosine 5′-diphosphate (ADP) and its analogs, cytidine 5′-di-and triphosphate (CDP, CTP) and their analogs, and dinucleoside polyphosphate compounds.
REFERENCES:
patent: 3846402 (1974-11-01), Eckstein et al.
patent: 5641750 (1997-06-01), Louis
patent: 5667968 (1997-09-01), LaVail et al.
patent: 5763447 (1998-06-01), Jacobus et al.
patent: 5837861 (1998-11-01), Pendergast et al.
patent: 5900407 (1999-05-01), Yerxa et al.
patent: 6596725 (2003-07-01), Peterson et al.
patent: 20010031743 (2001-10-01), Peterson et al.
patent: WO 9834942 (1998-08-01), None
patent: WO 9909998 (1999-04-01), None
patent: WO 9961012 (1999-12-01), None
patent: WO 0050024 (2000-08-01), None
patent: WO 0108691 (2001-02-01), None
Abbracchio, Maria and Geoffrey Burnstock, “Purinergic Signalling: Pathophysiological Roles,”Jpn J Pharmacol,78:113-145 (1998).
Abbracchio, M. P. et al., “Effects of ATP Analogues and Basic Fibroblast Growth Factor on Astroglial Cell Differentiation in Primary Cultures of Rat Striatum,”Int J Dev Neurosci,13(7):685-693 (1995).
Ambati, Jayakrishna. et al., “Tansscleral Delivery of Bioactive Protein to the Choroid and Retina,”Invest. Ophthalmol. Vis. Sci.,41(5):1186-1191 (2000).
Bolego, Chiara. et al., “Characterization of the signalling pathways involved in ATP and basic fibroblast growth factor-induced astrogliosis,”Br J Pharmacol,121:1692-1699 (1997).
Boyer, Jose L. et al., “Identification of potent P2y-purinoceptor agonists that are derivatives of adenosince 5′-monophosphate,” Br. J. Pharmacol. 118:1959-1964 (1996).
Bush, Toby G. et al., “Leukocyte Infiltration, Neuronal Degeneration, and Neuite Outgrowth after Ablation of Scar-Forming, Reactive Astrocyted in Adult Transgenic Mice,” Neuron, 23:297-302 (1999).
Chen, Yongmei and Albert Y. Sun, “Activation of Transcription Factor AP-1 by Extracellular ATP in PC123 Cells,”Neurochem Res,23(4):543-550 (1998).
Eddleston, M. and L. Mucke, “Molecular Profile of Reactive Astrocytes-Implications for their role in Neurologic Disease,” Neuroscience, 54(1):15-36 (1993).
Hatten, Mary, et al., “Astroglia in CNS Injury,” GLIA, 4:233-243 (1991).
Idestrup, C.P. and M.W. Salter, “P2Y and P2U Receptors Differentially Release Intracellular Ca2+ via the Phospholipase C/Inositol 1,4,5-Triphosphate Pathway in Astrocytes from the Dorsal Spinal Cord,”Neuroscience,86(3):913-923 (1998).
Kandel, Eric and James H. Schwartz,Principles of Neuroscience,1979, 2nd Ed., Elsevier, New York, (1985).
Kirischuk, S. et al., “Activation of P2-purinoreceptors triggered Ca2+ release from InsP2-sensitive internal stores in mammalian olifodendrocytes,”J Physiol(Lond), 483(1):41-57 (1995).
LaVail, Matthew M. et al., “Multiple growth factores, cytokinesm and neurotrophins rescue photoreceptors from the damaging effects of constant light,”Proc. Natl Acad Sci.,89:11249-11253 (1992).
Lazarowski, Eduardo. et al., “Pharmacological selectivity of the coloned human P2u-purinoceptor: potent activation by diadenosine tetraphosphate,”Brit. J. Pharm.116:1619-1627 (1995).
Liu, Yao and Masato Wakakura, “P1-/P2-Purinergic Receptors on Cultured Rabbit Retinal Muller Cells,”Jpn J Ophthalmol,42:33-40 (1998).
Lyons, Susan. et al., “Schwann Cells Exhibit P2y Purinergic Receptors that Regulate Intracellular Calcium and Are Up-Regulated by Cyclic AMP Analogues,”J Neurochem,63:552-560 (1994).
Neary, J.T., et al., “Synergistic Activation of DNA Synthesis in Astrocytes by Fibroblast Growth Factors and Extracellular ATP,”J Neurochem,63(2):490-494 (1994).
Neary, Joseph T. and Qing Zhu, “Signaling by ATP receptors in astrocytes,”Neuroreport,5(1315):1617-1620, (1994).
Neary, J. T., et al., “Destabilization of Glial Fibrillary Acidic Protein mRNA in Astrocytes by Ammonia and Protection by Extracellualr ATP,”J Neurochem,63(6):2021-2027 (1994).
Neary, Joseph T., et al., “Mitogenic Signaling by ATP/P2Y Purinergic Receptors in Astocytes: Involvement of a Calcium-Independent Protein Kinase C, Extracellular Signal-Regulated Protein Kinase Pathway Distinct from the Phosphatidylinositol-Specific Phospholipase C/Calcium Pathway,”J Neurosci,19:4211-20, (1999).
Ng, Kam-mui and Leslie E. Orgel, “The action of a water-soluble carbodiimide on adenosine-′5 polyphosphates,”Nucleic Acids Res.15(8):3572-3580 (1987).
Peterson, Ward M., et al., “Extracellualr ATP Activates Calcium Signaling, Ion, and Fluid Transport In Retinal Pigment Epithelium,”J Neurosci,17(7):2324-2337 (1997).
Priller, J., et al., “Stimulation of P2Y-Purinoceptors on Astrocytes Results in Immediate Early Gene Expression and Potentiation of Neuropeptide Action,”Neuroscience,85(2):521-5, 1998.
R.S. Goody and F. Eckstein, “Thiophosphate Analogs of Nucleoside Di- and Triphosphates,”J. Am. Chem. Soc.93: 6252-6257 (1971).
Ralevic, Vera and Geoffrey Burnstock, “Receptors for Purines and Pyrimidines,”Pharmacol Rev,50:413-492 (1998).
Rapaport, Eliezer., et al., “HeLa cell DNA polymerase a is tightly associated with tryptophanyl-tRNA synthetase and diadenosine 5′, 5′′′, -P1, P4-tetraphosphate binding activities,”Proc. Natl. Acad. Sci.USA 78(2): 838-842 (1981).
Rathbone, Michael P., et al., “Purine Nucleosides and Nucleotides Stimulate Proliferation of a Wide Range of Cell Types,”In Vitro Cell Dev Biol,28A:529-36, (1992).
Ridet, J.L., et al., “Reactive astrocytes:cellular and molecular cues to biological function,” Trands Neurosci, 20(12):570-577 (1997).
Segal, Rosalind A. and Michael E. Greenberg, “Intracellular Signaling Pathways Activated By Neurotrophic Factors,”Annu Rev Neurosci,19:463-89, (1996).
Vestn Oftalmol.,Jan.-Feb.; :24-6, (1969).
Wu, Delon., et al.,Mol Pharmacol,53(2) :346 (1998).
International Search Report.
Sullivan, et al., “Identification and Characterization of P2Y2Nucleotide Receptors in Human Retinal Pigment Epithelial Cells,”Journal of Neuroscience Research49:43-52 (1997).
Barts Samuel
Howrey Simon Arnold & White
Inspire Pharmaceuticals Inc.
Kung Viola T.
Owens Howard V.
LandOfFree
Method for treating retinal degeneration with purinergic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating retinal degeneration with purinergic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating retinal degeneration with purinergic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3423069